Overview

Description

  • NatureSynthetic

Associated products

Specifications

Our Abpromise guarantee covers the use of ab5890 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking

  • Purity> 95 % SDS-PAGE.

  • FormLiquid
  • Additional notes


    This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and mouse PDE6 beta, catalog ab5663. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (70-fold) for competitive inhibition of antibody-protein binding reactions.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

General Info

  • Alternative names
    • 5''-cyclic phosphodiesterase subunit beta
    • Congenital stationary night blindness 3 autosomal dominant
    • CSNB 3
    • CSNB3
    • CSNBAD2
    • GMP PDE beta
    • GMP-PDE beta
    • PDE 6 beta
    • PDE 6B
    • PDE6B
    • PDE6B_HUMAN
    • PDEB
    • Phosphodiesterase 6B
    • Phosphodiesterase 6B cGMP specific rod beta
    • Rd 1
    • Rd1
    • Rod cGMP phosphodiesterase beta subunit
    • Rod cGMP specific 3' 5' cyclic phosphodiesterase beta subunit
    • Rod cGMP-specific 3''
    • RP40
    see all
  • FunctionThis protein participates in processes of transmission and amplification of the visual signal. Necessary for the formation of a functional phosphodiesterase holoenzyme.
  • Involvement in diseaseDefects in PDE6B are the cause of retinitis pigmentosa type 40 (RP40) [MIM:613801]. RP40 is a retinal dystrophy belonging to the group of pigmentary retinopathies. Retinitis pigmentosa is characterized by retinal pigment deposits visible on fundus examination and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptors. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.
    Defects in PDE6B are a cause of congenital stationary night blindness autosomal dominant type 2 (CSNBAD2) [MIM:163500]; also known as congenital stationary night blindness Rambusch type. Congenital stationary night blindness is a non-progressive retinal disorder characterized by impaired night vision.
  • Sequence similaritiesBelongs to the cyclic nucleotide phosphodiesterase family.
    Contains 2 GAF domains.
  • Cellular localizationMembrane.
  • Information by UniProt

References for PDE6 beta peptide (ab5890)

ab5890 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab5890.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"